↑ Breast Cancer. NCI. Retrieved 29 June 2014. 1 2 3 4 5 Breast Cancer Treatment (PDQ®). NCI. 23 May 2014. Retrieved 29 June 2014. ↑ Saunders, Christobel; Jassal, Sunil (2009). Breast cancer (1. ed.). Oxford: Oxford University Press. p.xa0Chapter 13. ISBNxa0978-0-19-955869-8. 1 2 3 4 5 6 World Cancer Report 2014. World Health Organization. 2014. pp.xa0Chapter 5.2. ISBNxa092-832-0429-8. 1 2 3 4 5 Gøtzsche PC, Jørgensen KJ (4 June 2013). Screening for breast cancer with mammography.. The Cochrane database of systematic reviews 6: CD001877. doi:10.1002/14651858.CD001877.pub5. PMIDxa023737396. ↑ Nelson, HD; Tyne, K; Naik, A; Bougatsos, C; Chan, B; Nygren, P; Humphrey, L (November 2009). Screening for Breast Cancer: Systematic Evidence Review Update for the US Preventive Services Task Force [Internet].. PMIDxa020722173. 1 2 Siu, Albert L. (12 January 2016). Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. doi:10.7326/M15-2886. ↑ American College of Surgeons (September 2013), Five Things Physicians and Patients Should QuestionChoosing Wisely: an initiative of the ABIM Foundation (American College of Surgeons), retrieved 2 January 2013 1 2 3 Breast Cancer Treatment (PDQ®). NCI. 26 June 2014. Retrieved 29 June 2014. 1 2 World Cancer Report (PDF). International Agency for Research on Cancer. 2008. Retrieved 26 February 2011. ↑ Cancer Survival in England: Patients Diagnosed 2007–2011 and Followed up to 2012 (PDF). Office for National Statistics. 29 October 2013. Retrieved 29 June 2014. ↑ SEER Stat Fact Sheets: Breast Cancer. NCI. Retrieved 18 June 2014. 1 2 World Cancer Report 2014. World Health Organization. 2014. pp.xa0Chapter 1.1. ISBNxa092-832-0429-8. ↑ Male Breast Cancer Treatment. National Cancer Institute. 2014. Retrieved 29 June 2014. 1 2 3 4 Merck Manual of Diagnosis and Therapy (February 2003). Breast Disorders: Breast Cancer. Retrieved 5 February 2008. 1 2 American Cancer Society (2007). Cancer Facts & Figures 2007 (PDF). Archived from the original (PDF) on 10 April 2007. Retrieved 26 April 2007. ↑ Watson M (2008). Assessment of suspected cancer. InnoAiT 1 (2): 94–107. doi:10.1093/innovait/inn001. ↑ eMedicine (23 August 2006). Breast Cancer Evaluation. Retrieved 5 February 2008. ↑ National Cancer Institute (27 June 2005). Pagets Disease of the Nipple: Questions and Answers. Retrieved 6 February 2008. ↑ answers.com. Oncology Encyclopedia: Cystosarcoma Phyllodes. Retrieved 10 August 2010. ↑ Lacroix M (December 2006). Significance, detection and markers of disseminated breast cancer cells. Endocrine-Related Cancer (Bioscientifica) 13 (4): 1033–67. doi:10.1677/ERC-06-0001. PMIDxa017158753. ↑ National Cancer Institute (1 September 2004). Metastatic Cancer: Questions and Answers. Retrieved 6 February 2008. ↑ Interpreting Signs and Symptoms. Lippincott Williams & Wilkins. 2007. pp.xa099–. ISBNxa0978-1-58255-668-0. ↑ Merck Manual of Diagnosis and Therapy (February 2003). Breast Disorders: Overview of Breast Disorders. Retrieved 5 February 2008. 1 2 3 Hayes,, James; Ricahrdson, Ann; Frampton, Chris (15 November 2013). Population attributable risks for modifiable lifestyle factors and breast cancer in New Zealand women. IMJ 43 (11): 1198–1204. doi:10.1111/imj.12256. PMIDxa023910051. ↑ Reeder JG, Vogel VG (2008). Breast cancer prevention.. Cancer treatment and research 141: 149–64. doi:10.1007/978-0-387-73161-2_10. PMIDxa018274088. ↑ Am I at risk?. Breast Cancer Care. Retrieved 22 October 2013. ↑ Collaborative Group on Hormonal Factors in Breast Cancer (August 2002). Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease.. Lancet 360 (9328): 187–95. doi:10.1016/S0140-6736(02)09454-0. PMIDxa012133652. ↑ Yager JD, Davidson NE (2006). Estrogen carcinogenesis in breast cancer. New Engl J Med 354 (3): 270–82. doi:10.1056/NEJMra050776. PMIDxa016421368. ↑ Santoro, E., DeSoto, M., and Hong Lee, J (February 2009). Hormone Therapy and Menopause. National Research Center for Women & Families. CS1 maint: Multiple names: authors list (link) ↑ Light Pollution as new risk factor for human Breast and Prostate Cancers- Haim,Abraham; Portnov, Biris P. ,2013,ISBN 978-94-007-6220-6 1 2 Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, Cantor KP, Miller MD, Boyd NF, Millar J, Turcotte F (Jan 2011). Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009).. Tobacco control 20 (1): e2. doi:10.1136/tc.2010.035931. PMIDxa021148114. ↑ Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT (1 July 2012). Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. The Lancet 380 (9838): 219–29. doi:10.1016/S0140-6736(12)61031-9. PMCxa03645500. PMIDxa022818936. ↑ Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA (2015). Sedentary Time and Its Association With Risk for Disease Incidence, Mortality, and Hospitalization in Adults: A Systematic Review and Meta-analysis. Annals of Internal Medicine 162 (2): 123–32. doi:10.7326/M14-1651. PMIDxa025599350. ↑ Kahlenborn C, Modugno F, Potter DM, Severs WB (Oct 2006). Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis.. Mayo Clinic proceedings. Mayo Clinic 81 (10): 1290–302. doi:10.4065/81.10.1290. PMIDxa017036554. 1 2 Veljković M, Veljković S (Sep 2010). [The risk of breast cervical, endometrial and ovarian cancer in oral contraceptive users].. Medicinski pregled 63 (9–10): 657–61. doi:10.2298/mpns1010657v. PMIDxa021446095. 1 2 Casey PM, Cerhan JR, Pruthi S (January 2008). Oral contraceptive use and risk of breast cancer.. Mayo Clinic proceedings. Mayo Clinic 83 (1): 86–90; quiz 90–1. doi:10.4065/83.1.86. PMIDxa018174010. ↑ Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, Bernard L, Maisonneuve P, Gandini S (August 2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.. European journal of cancer (Oxford, Englandxa0: 1990) 46 (12): 2275–84. doi:10.1016/j.ejca.2010.04.018. PMIDxa020537530. ↑ Gaffield ME, Culwell KR, Ravi A (October 2009). Oral contraceptives and family history of breast cancer.. Contraception 80 (4): 372–80. doi:10.1016/j.contraception.2009.04.010. PMIDxa019751860. ↑ Yang L, Jacobsen KH (December 2008). A systematic review of the association between breastfeeding and breast cancer.. Journal of Womens Health 17 (10): 1635–45. doi:10.1089/jwh.2008.0917. PMIDxa019049358. ↑ Russo J, Russo IH (1980). Susceptibility of the mammary gland to carcinogenesis. II. Pregnancy interruption as a risk factor in tumor incidence. Am J Pathol 100 (2): 505–506. PMCxa01903536. PMIDxa06773421. In contrast, abortion is associated with increased risk of carcinomas of the breast. The explanation for these epidemiologic findings is not known, but the parallelism between the DMBA-induced rat mammary carcinoma model and the human situation is striking.xa0... Abortion would interrupt this process, leaving in the gland undifferentiated structures like those observed in the rat mammary gland, which could render the gland again susceptible to carcinogenesis. ↑ Beral V, Bull D, Doll R, Peto R, Reeves G (27 March 2004). Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries.. Lancet 363 (9414): 1007–16. doi:10.1016/S0140-6736(04)15835-2. PMIDxa015051280. ↑ Blackburn GL, Wang KA (September 2007). Dietary fat reduction and breast cancer outcome: results from the Womens Intervention Nutrition Study (WINS).. The American Journal of Clinical Nutrition 86 (3): s878–81. PMIDxa018265482. ↑ Boffetta P, Hashibe M, La Vecchia C, Zatonski W, Rehm J (August 2006). The burden of cancer attributable to alcohol drinking. International Journal of Cancer 119 (4): 884–7. doi:10.1002/ijc.21903. PMIDxa016557583. ↑ BBC report Weight link to breast cancer risk ↑ Kaiser J (29 November 2013). Cancer. Cholesterol forges link between obesity and breast cancer.. Science 342 (6162): 1028. doi:10.1126/science.342.6162.1028. PMIDxa024288308. ↑ Aceves C, Anguiano B, Delgado G (April 2005). Is iodine a gatekeeper of the integrity of the mammary gland?. Journal of Mammary Gland Biology and Neoplasia 10 (2): 189–96. doi:10.1007/s10911-005-5401-5. PMIDxa016025225. ↑ Mourouti, N; Kontogianni, MD; Papavagelis, C; Panagiotakos, DB (February 2015). Diet and breast cancer: a systematic review.. International journal of food sciences and nutrition 66 (1): 1–42. doi:10.3109/09637486.2014.950207. PMIDxa025198160. ↑ Aubrey, Allison (1 February 2016). A Diet High In Fiber May Help Protect Against Breast Cancer. NPR. Retrieved 1 February 2016. 1 2 American Cancer Society (2005). Breast Cancer Facts & Figures 2005–2006 (PDF). Archived from the original (PDF) on 13 June 2007. Retrieved 26 April 2007. ↑ Wang XS, Armstrong ME, Cairns BJ, Key TJ, Travis RC (March 2011). Shift work and chronic disease: the epidemiological evidence.. Occupational Medicine 61 (2): 78–89. doi:10.1093/occmed/kqr001. PMCxa03045028. PMIDxa021355031. ↑ Brody JG, Rudel RA, Michels KB, Moysich KB, Bernstein L, Attfield KR, Gray S (June 2007). Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention?. Cancer 109 (12 Suppl): 2627–34. doi:10.1002/cncr.22656. PMIDxa017503444. ↑ Hendrick RE (October 2010). Radiation doses and cancer risks from breast imaging studies.. Radiology 257 (1): 246–53. doi:10.1148/radiol.10100570. PMIDxa020736332. 1 2 3 Boris Pasche (2010). Cancer Genetics (Cancer Treatment and Research). Berlin: Springer. pp.xa019–20. ISBNxa01-4419-6032-5. 1 2 3 Gage M, Wattendorf D, Henry LR (1 April 2012). Translational advances regarding hereditary breast cancer syndromes. Journal of surgical oncology 105 (5): 444–51. doi:10.1002/jso.21856. PMIDxa022441895. ↑ Colditz, Graham A.; Kaphingst, Kimberly A.; Hankinson, Susan E.; Rosner, Bernard (19 February 2012). Family history and risk of breast cancer: nurses health study. Breast Cancer Research and Treatment 133 (3): 1097–1104. doi:10.1007/s10549-012-1985-9. ISSNxa00167-6806. PMCxa03387322. PMIDxa022350789. ↑ Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.. Lancet 358 (9291): 1389–99. 27 October 2001. doi:10.1016/S0140-6736(01)06524-2. PMIDxa011705483. ↑ Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, OMeara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, Miglioretti DL (1 May 2012). Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis.. Annals of Internal Medicine 156 (9): 635–48. doi:10.1059/0003-4819-156-9-201205010-00006. PMCxa03561467. PMIDxa022547473. ↑ Kolata, Gina (23 September 2012). Genetic Study Finds 4 Distinct Variations of Breast Cancer. The New York Times. Retrieved 23 September 2012. ↑ Understanding Breast Changes – National Cancer Institute. Archived from the original on 27 May 2010. ↑ Lobular carcinoma in situ: Marker for breast cancer risk. MayoClinic.com. ↑ Breast Cancer Treatment. National Cancer Institute. ↑ Afonso N, Bouwman D (August 2008). Lobular carcinoma in situ. Eur. J. Cancer Prev. 17 (4): 312–6. doi:10.1097/CEJ.0b013e3282f75e5d. PMIDxa018562954. ↑ Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, Hirunpat S, Woodtichartpreecha P, Boonlikit S, Teerawattananon Y, Thakkinstian A (2013). Risk factors of breast cancer: a systematic review and meta-analysis. Asian Pacific Journal of Public Health 25 (5): 368–387. doi:10.1177/1010539513488795. PMIDxa023709491. ↑ Adrian Lee; Carlos Arteaga (14 December 2009). 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium (PDF). Sunday Morning Year-End Review. Archived from the original (PDF) on 13 August 2013. ↑ Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T (August 2006). Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochimica et Biophysica Acta 1766 (1): 63–78. doi:10.1016/j.bbcan.2006.03.001. PMIDxa016675129. ↑ Haslam SZ, Woodward TL (June 2003). Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland.. Breast Cancer Res. 5 (4): 208–15. doi:10.1186/bcr615. PMCxa0165024. PMIDxa012817994. ↑ Wiseman BS, Werb Z (May 2002). Stromal effects on mammary gland development and breast cancer. Science 296 (5570): 1046–9. doi:10.1126/science.1067431. PMCxa02788989. PMIDxa012004111. ↑ Jardé T, Perrier S, Vasson MP, Caldefie-Chézet F (January 2011). Molecular mechanisms of leptin and adiponectin in breast cancer. Eur. J. Cancer 47 (1): 33–43. doi:10.1016/j.ejca.2010.09.005. PMIDxa020889333. ↑ Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (October 1999). A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention 8 (10): 843–54. PMIDxa010548311. ↑ Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL (January 2008). Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299 (2): 194–201. doi:10.1001/jama.2007.55-a. PMCxa02714486. PMIDxa018182601. ↑ Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR (February 1998). Involvement of Brca2 in DNA repair. Mol. Cell 1 (3): 347–57. doi:10.1016/S1097-2765(00)80035-0. PMIDxa09660919. ↑ Marietta C, Thompson LH, Lamerdin JE, Brooks PJ (May 2009). Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis. Mutat. Res. 664 (1–2): 77–83. doi:10.1016/j.mrfmmm.2009.03.011. PMCxa02807731. PMIDxa019428384. ↑ Theruvathu JA, Jaruga P, Nath RG, Dizdaroglu M, Brooks PJ (2005). Polyamines stimulate the formation of mutagenic 1,N2-propanodeoxyguanosine adducts from acetaldehyde. Nucleic Acids Res. 33 (11): 3513–20. doi:10.1093/nar/gki661. PMCxa01156964. PMIDxa015972793. ↑ Wooster R, Weber BL (June 2003). Breast and ovarian cancer. N. Engl. J. Med. 348 (23): 2339–47. doi:10.1056/NEJMra012284. PMIDxa012788999. ↑ Levin B, Lech D, Friedenson B (2012). Evidence that BRCA1- or BRCA2-associated cancers are not inevitable. Mol. Med. 18: 1327–37. doi:10.2119/molmed.2012.00280. PMCxa03521784. PMIDxa022972572. ↑ Kouros-Mehr H, Kim JW, Bechis SK, Werb Z (Apr 2008). GATA-3 and the regulation of the mammary luminal cell fate.. Current opinion in cell biology 20 (2): 164–70. doi:10.1016/j.ceb.2008.02.003. PMCxa02397451. PMIDxa018358709. ↑ Saslow D, Hannan J, Osuch J, Alciati MH, Baines C, Barton M, Bobo JK, Coleman C, Dolan M, Gaumer G, Kopans D, Kutner S, Lane DS, Lawson H, Meissner H, Moorman C, Pennypacker H, Pierce P, Sciandra E, Smith R, Coates R (2004). Clinical breast examination: practical recommendations for optimizing performance and reporting. CA: A Cancer Journal for Clinicians 54 (6): 327–344. doi:10.3322/canjclin.54.6.327. PMIDxa015537576. ↑ Yu YH, Liang C, Yuan XZ (2010). Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review.. Breast cancer research and treatment 120 (2): 469–79. doi:10.1007/s10549-010-0750-1. PMIDxa020130983. ↑ Merck Manual, Professional Edition, Ch. 253, Breast Cancer. ↑ American Society of Clinical Oncology, Five Things Physicians and Patients Should Question (PDF), Choosing Wisely: an initiative of the ABIM Foundation (American Society of Clinical Oncology), retrieved 14 August 2012 ↑ Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC (2009). Breast cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Networkxa0: JNCCN 7 (2): 122–192. PMIDxa019200416. CS1 maint: Multiple names: authors list (link) ↑ Kumar, Vinay; Abul Abbas (2010). Robbins and Cotran Pathologic Basis of Disease. Philadelphia: Saunders, an imprint of Elsevier inc. p.xa01090. ISBNxa0978-1-4160-3121-5. ↑ Sotiriou C, Pusztai L (February 2009). Gene-expression signatures in breast cancer. N. Engl. J. Med. 360 (8): 790–800. doi:10.1056/NEJMra0801289. PMIDxa019228622. ↑ Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (October 2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (16): 1673–84. doi:10.1056/NEJMoa052122. PMIDxa016236738. 1 2 3 American Institute for Cancer Research/ World Cancer Research Fund, Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective ↑ Eliassen AH, Hankinson SE, Rosner B, Holmes MD, Willett WC (October 2010). Physical activity and risk of breast cancer among postmenopausal women. Arch. Intern. Med. 170 (19): 1758–64. doi:10.1001/archinternmed.2010.363. PMCxa03142573. PMIDxa020975025. ↑ Zheng JS, Hu XJ, Zhao YM, Yang J, Li D (2013). Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ 346: f3706. doi:10.1136/bmj.f3706. PMIDxa023814120. ↑ Wu, AH; Yu, MC; Tseng, CC; Pike, MC (15 January 2008). Epidemiology of soy exposures and breast cancer risk.. British Journal of Cancer 98 (1): 9–14. doi:10.1038/sj.bjc.6604145. PMIDxa018182974. ↑ Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB (1999). Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 (2): 77–84. doi:10.1056/NEJM199901143400201. PMIDxa09887158. ↑ Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG (2001). Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 and BRCA2 mutations. N Engl J Med 345 (3): 159–164. doi:10.1056/NEJM200107193450301. PMIDxa011463009. 1 2 Lostumbo, L; Carbine, NE; Wallace, J (10 November 2010). Prophylactic mastectomy for the prevention of breast cancer.. The Cochrane database of systematic reviews (11): CD002748. doi:10.1002/14651858.CD002748.pub3. PMIDxa021069671. ↑ Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 160: 271–281. 24 December 2013. doi:10.7326/M13-2747. 1 2 3 Nelson HD, Smith ME, Griffin JC, Fu R (16 April 2013). Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.. Annals of Internal Medicine 158 (8): 604–14. doi:10.7326/0003-4819-158-8-201304160-00005. PMIDxa023588749. ↑ Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL (25 May 2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.. Lancet 381 (9880): 1827–34. doi:10.1016/S0140-6736(13)60140-3. PMIDxa023639488. ↑ Moyer VA (24 September 2013). Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.. Annals of Internal Medicine. doi:10.7326/0003-4819-159-10-201311190-00718. PMIDxa024061472. ↑ Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL (31 March 2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. The Lancet 381 (9880): 1827–34. doi:10.1016/S0140-6736(13)60140-3. PMIDxa023639488. ↑ Screening. Centers for Disease Control and Prevention. Retrieved 17 November 2015. ↑ Screening for Breast Cancer. US Preventative Services Task Force. December 2009. Retrieved 24 December 2012. ↑ Kösters JP, Gøtzsche PC (2003). Cochrane Database of Systematic Reviews. Cochrane Database Syst Rev (2): CD003373. doi:10.1002/14651858.CD003373. PMIDxa012804462. ↑ Breast Cancer and Mammograms. WebMD. Retrieved 24 December 2012. ↑ Biesheuvel C, Weigel S, Heindel W (2011). Mammography Screening: Evidence, History and Current Practice in Germany and Other European Countries.. Breast care (Basel, Switzerland) 6 (2): 104–109. doi:10.1159/000327493. PMIDxa021673820. ↑ Tonelli M, Connor Gorber S, Joffres M, Dickinson J, Singh H, Lewin G, Birtwhistle R, Fitzpatrick-Lewis D, Hodgson N, Ciliska D, Gauld M, Liu YY (22 November 2011). Recommendations on screening for breast cancer in average-risk women aged 40–74 years.. Canadian Medical Association Journal 183 (17): 1991–2001. doi:10.1503/cmaj.110334. PMCxa03225421. PMIDxa022106103. ↑ Breast Cancer: Screening. United States Preventive Services Task Force. Archived from the original on 16 June 2013. ↑ Welch HG, Passow HJ (30 December 2013). Quantifying the Benefits and Harms of Screening Mammography.. JAMA internal medicine 174 (3): 448–54. doi:10.1001/jamainternmed.2013.13635. PMIDxa024380095. ↑ Gøtzsche PC, Nielsen M (2011). Screening for breast cancer with mammography. Cochrane Database Syst Rev (1): CD001877. doi:10.1002/14651858.CD001877.pub4. PMIDxa021249649. ↑ Screening for breast cancer with mammography. Cochrane Nordic. 27 August 2015. Retrieved 15 October 2015. ↑ Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.. Annals of Internal Medicine 151 (10): 716–26, W–236. 17 November 2009. doi:10.1059/0003-4819-151-10-200911170-00008. PMIDxa019920272. ↑ Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, Piccart-Gebhart MJ, de Azambuja E (August 2011). Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Annals of Oncology 23 (4): 853–9. doi:10.1093/annonc/mdr352. PMIDxa021821551. ↑ Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010). Aspirin Intake and Survival After Breast Cancer. Journal of Clinical Oncology 28 (9): 1467–72. doi:10.1200/JCO.2009.22.7918. PMCxa02849768. PMIDxa020159825. ↑ Ting Bao; Michelle A Rudek (2011). The Clinical Pharmacology of Anastrozole. European Oncology & Haematology 7 (2): 106–8. ↑ Burstein, HJ; Temin, S; Anderson, H; Buchholz, TA; Davidson, NE; Gelmon, KE; Giordano, SH; Hudis, CA; Rowden, D; Solky, AJ; Stearns, V; Winer, EP; Griggs, JJ (27 May 2014). Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.. Journal of clinical oncologyxa0: official journal of the American Society of Clinical Oncology 32 (21): 2255–69. doi:10.1200/JCO.2013.54.2258. PMIDxa024868023. ↑ Early Breast Cancer Trialists Collaborative Group (23 July 2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet 386: 1341–1352. doi:10.1016/S0140-6736(15)61074-1. ↑ Petit T, Dufour P, Tannock I (June 2011). A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. Endocr. Relat. Cancer 18 (3): R79–89. doi:10.1530/ERC-10-0162. PMIDxa021502311. ↑ Jahanzeb M (August 2008). Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin. Breast Cancer 8 (4): 324–33. doi:10.3816/CBC.2008.n.037. PMIDxa018757259. ↑ Entrez Gene: ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian). Retrieved 17 November 2015. ↑ Herceptin (trastuzumab) Adjuvant HER2+ Breast Cancer Therapy Pivotal Studies and Efficacy Data. Herceptin.com. Retrieved 8 May 2010. ↑ Massarut S, Baldassare G, Belleti B, Reccanello S, DAndrea S, Ezio C, Perin T, Roncadin M, Vaidya JS (2006). Intraoperative radiotherapy impairs breast cancer cell motility induced by surgical wound fluid. J Clin Oncol 24 (18S): 10611. ↑ Belletti B, Vaidya JS, DAndrea S, Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E, Reccanello S, Veronesi A, Canzonieri V, Trovò MG, Zaenker KS, Colombatti A, Baldassarre G, Massarut S (March 2008). Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin. Cancer Res. 14 (5): 1325–32. doi:10.1158/1078-0432.CCR-07-4453. PMIDxa018316551. ↑ Jayant S Vaidya. TARGIT IORT for breast cancer. Jayantvaidya.org. Retrieved 15 October 2015. ↑ Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M (July 2010). Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 376 (9735): 91–102. doi:10.1016/S0140-6736(10)60837-9. PMIDxa020570343. ↑ Radiation Therapy. Breastcancer.org. Retrieved 17 November 2015. ↑ Breast Cancer: Breast Disorders: Merck Manual Professional. Merck.com. Retrieved 8 May 2010. ↑ Surgery Choices for Women with Early Stage Breast Cancer (PDF). National Cancer Institute and the National Research Center for Women & Families. August 2004. Archived from the original (PDF) on 13 August 2013. ↑ Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN (December 2009). High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J. Clin. Oncol. 27 (34): 5700–6. doi:10.1200/JCO.2009.23.2025. PMCxa02792998. PMIDxa019884543. Lay summary – ScienceDaily. ↑ Breast Cancer: Breast Disorders: Merck Manual Professional. Merck.com. Retrieved 14 November 2010. ↑ Elston CW, Ellis IO (November 1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (5): 403–10. doi:10.1111/j.1365-2559.1991.tb00229.x. PMIDxa01757079. ↑ Peppercorn J (2009). Breast Cancer in Women Under 40. Oncology 23 (6). ↑ Brandt, Jasmine; Garne, Jens; Tengrup, Ingrid; Manjer, Jonas (2015). Age at diagnosis in relation to survival following breast cancer: a cohort study. World Journal of Surgical Oncology 13 (1): 33. doi:10.1186/s12957-014-0429-x. ISSNxa01477-7819. ↑ Gierach GL, Ichikawa L, Kerlikowske K, Brinton LA, Farhat GN, Vacek PM, Weaver DL, Schairer C, Taplin SH, Sherman ME (August 2012). Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. Journal of National Cancer Institute 104 (16): 1218–27. doi:10.1093/jnci/djs327. PMIDxa022911616. ↑ Amro Masarwah; Päivi Auvinen; Mazen Sudah; Suvi Rautiainen; Anna Sutela; Outi Pelkonen; Sanna Oikari; Veli-Matti Kosma; Ritva Vanninen; et al. (2015). Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer. European Radiology 25: 1875–1882. doi:10.1007/s00330-015-3626-2. PMIDxa025735512. ↑ Klein, Judith. Differences in male breast cancer stage, tumor size at diagnosis, and survival rate between metropolitan and nonmetropolitan regions. Proquest. Retrieved 7 December 2012. ↑ Pritchard KI (2009). Ovarian Suppression/Ablation in Premenopausal ER-Positive Breast Cancer Patients. Oncology 23 (1). 1 2 Robb C, Haley WE, Balducci L, Extermann M, Perkins EA, Small BJ, Mortimer J (April 2007). Impact of breast cancer survivorship on quality of life in older women. Critical Reviews in Oncology/hematology 62 (1): 84–91. doi:10.1016/j.critrevonc.2006.11.003. PMIDxa017188505. ↑ WHO Disease and injury country estimates. World Health Organization. 2009. Retrieved 11 November 2009. 1 2 3 McGuire, A; Brown, JA; Malone, C; McLaughlin, R; Kerin, MJ (22 May 2015). Effects of age on the detection and management of breast cancer.. Cancers 7 (2): 908–29. doi:10.3390/cancers7020815. PMIDxa026010605. 1 2 3 World Cancer Report. International Agency for Research on Cancer. 2008. Missing or empty _BAR_url= (help); _BAR_access-date= requires _BAR_url= (help) (cancer statistics often exclude non-melanoma skin cancers such as basal-cell carcinoma, which are common but rarely fatal) ↑ Breast cancer: prevention and control. World Health Organization. Archived from the original on 6 September 2015. ↑ World Cancer Report 2014. International Agency for Research on Cancer, World Health Organization. 2014. ISBNxa0978-92-832-0432-9. ↑ Stewart B. W. and Kleihues P. (Eds): World Cancer Report. IARCPress. Lyon 2003 Archived 20 October 2008 at the Wayback Machine. ↑ Laurance, Jeremy (29 September 2006). Breast cancer cases rise 80% since Seventies. The Independent (London). Archived from the original on 25 April 2008. Retrieved 9 October 2006. ↑ Breast Cancer: Statistics on Incidence, Survival, and Screening. Imaginis Corporation. 2006. Retrieved 9 October 2006. ↑ Breast Cancer: Breast Cancer in Young Women WebMD. Retrieved 9 September 2009 ↑ Nearly 85% of women diagnosed with breast cancer now survive for 5 year or more Office for National Statistics, 2013 1 2 3 Olson, James Stuart (2002). Bathshebas breast: women, cancer & history. Baltimore: The Johns Hopkins University Press. pp.xa09–13. ISBNxa00-8018-6936-6. 1 2 Oldest evidence of breast cancer found in Egyptian skeleton. Reuters. 24 March 2015. Retrieved 25 March 2015. ↑ The History of Cancer. American Cancer Society. 25 March 2002. Retrieved 9 October 2006. 1 2 Olson 2002, pp.xa032–33 ↑ Yalom, Marilyn (1997). A history of the breast. New York: Alfred A. Knopf. p.xa0234. ISBNxa00-679-43459-3. 1 2 3 4 Aronowitz, Robert A. (2007). Unnatural history: breast cancer and American society. Cambridge, UK: Cambridge University Press. pp.xa022–24. ISBNxa00-521-82249-1. ↑ History of Breast Cancer. Random History. 27 February 2008. Retrieved 8 May 2010. 1 2 3 4 5 6 7 Olson 2002, pp.xa0102–6 ↑ Olson 2002, p.xa01 ↑ Marc Lacroix (2011). A Concise History of Breast Cancer. USA: Nova Science Publishers. pp.xa059–68. ISBNxa0978-1-61122-305-7. ↑ Olson 2002, pp.xa026,28,229 ↑ Alfredo Morabia (2004). A History of Epidemiologic Methods and Concepts. Boston: Birkhauser. pp.xa0301–302. ISBNxa03-7643-6818-7. Retrieved 31 December 2007. 1 2 Sulik, Gayle A. (2010). Pink Ribbon Blues: How Breast Cancer Culture Undermines Womens Health. USA: Oxford University Press. pp.xa0200–3. ISBNxa00-19-974045-3. OCLCxa0535493589. ↑ Sulik 2010, pp.xa037–38 ↑ Sulik 2010, p.xa04 ↑ Bob Riter. History of Breast Cancer Advocacy. Cancer Resource Center of the Finger Lakes. Retrieved 29 June 2013. ↑ Sulik 2010, pp.xa027–72 ↑ Sulik 2010, pp.xa0359–361 ↑ Sulik 2010, pp.xa0366–8 ↑ Landeman, Anne (11 June 2008). Pinkwashing: Can Shopping Cure Breast Cancer?. Center for Media and Democracy. ↑ Sulik 2010, pp.xa0365–6 ↑ Sulik 2010, pp.xa0372–4 ↑ Breast cancer month overshadowed by pinkwashing 9 October 2010, Angela Mulholland, CTV.ca News 1 2 3 4 Ehrenreich, Barbara (November 2001). Welcome to Cancerland. Harpers Magazine. Archived from the original on 20 November 2010. ↑ Sulik 2010, p.xa057 1 2 Browne, Anthony (7 October 2001). Cancer bias puts breasts first. The Guardian (London). ↑ Arnst, Catherine (13 June 2007). A Gender Gap in Cancer. Bloomberg Businessweek. ISSNxa00007-7135. ↑ Olson 2002, pp.xa0199–200 ↑ Ave, Melanie (10 October 2006). Tampabay: All May Not Be in the Pink. St. Petersburg Times. 1 2 Aschwanden, Christie (17 August 2009). The Trouble with Mammograms. The Los Angeles Times. ↑ Azim HA, Jr; Santoro, L; Russell-Edu, W; Pentheroudakis, G; Pavlidis, N; Peccatori, FA (November 2012). Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies.. Cancer treatment reviews 38 (7): 834–42. doi:10.1016/j.ctrv.2012.06.004. PMIDxa022785217. ↑ Schedin, P (April 2006). Pregnancy-associated breast cancer and metastasis.. Nature reviews. Cancer 6 (4): 281–91. doi:10.1038/nrc1839. PMIDxa016557280. 1 2 3 4 5 6 7 Connie Henke Yarbro; Debra Wujcik; Barbara Holmes Gobel, eds. (2011). Cancer nursing: principles and practice (7 ed.). Jones & Bartlett Publishers. pp.xa0901–905. ISBNxa0978-1-4496-1829-2. 1 2 Gonçalves V, Sehovic I, Quinn G (2013). Childbearing attitudes and decisions of young breast cancer survivors: A systematic review. Human Reproduction Update 20 (2): 279–92. doi:10.1093/humupd/dmt039. PMCxa03922144. PMIDxa024077938. ↑ McNaught J, Reid RL, Provencher DM, et al. (July 2006). Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint Review and Committee Opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada. J Obstet Gynaecol Can 28 (7): 616–39. PMIDxa016924781. ↑ Management of the menopause after breast cancer, from the Royal Australian and New Zealand College of Obstetricians and Gynaecologists. College Statement C-Gyn 15. 1st Endorsed: February 2003. Current: November 2011. Review: November 2014 ↑ San Antonio Breast Cancer Symposium Abstracts, newsletters, and other reports of the meeting. Archived 16 May 2010 at the Wayback Machine. ↑ Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ (August 2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of Oncology 20 (8): 1319–29. doi:10.1093/annonc/mdp322. PMCxa02720818. PMIDxa019535820. ↑ Whats new in breast cancer research and treatment?. Cancer. Retrieved 17 November 2015. ↑ Fenretinide (4-HPR): A Preventive Chance for Women at Genetic and Familial Risk?. hindawi. Retrieved 17 November 2015. ↑ Sabel, MS (July 2014). Nonsurgical ablation of breast cancer: future options for small breast tumors.. Surgical oncology clinics of North America 23 (3): 593–608. doi:10.1016/j.soc.2014.03.009. PMIDxa024882353. 1 2 Roubidoux, MA; Yang, W; Stafford, RJ (March 2014). Image-guided ablation in breast cancer treatment.. Techniques in vascular and interventional radiology 17 (1): 49–54. doi:10.1053/j.tvir.2013.12.008. PMIDxa024636331. ↑ Current Status of Imaging-Guided Percutaneous Ablation of Breast Cancer. American Journal of Roentgenology 203 (2): 442–448. August 2014. doi:10.2214/AJR.13.11600. ↑ Jauliac S, López-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A (July 2002). The role of NFAT transcription factors in integrin-mediated carcinoma invasion.. Nature Cell Biology 4 (7): 540–4. doi:10.1038/ncb816. PMIDxa012080349. ↑ Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A (23 November 2005). Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT.. Molecular Cell 20 (4): 539–50. doi:10.1016/j.molcel.2005.10.033. PMIDxa016307918. 1 2 Fougère M, Gaudineau B, Barbier J, Guaddachi F, Feugeas JP, Auboeuf D, Jauliac S (15 April 2010). NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene.. Oncogene 29 (15): 2292–301. doi:10.1038/onc.2009.499. PMIDxa020101218. ↑ Gaudineau B, Fougère M, Guaddachi F, Lemoine F, de la Grange P, Jauliac S (1 October 2012). Lipocalin 2 (LCN2), the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.. Journal of Cell Science 125 (19): 4475–4486. doi:10.1242/jcs.099879. PMIDxa022767506. ↑ Duffy MJ (2001). Biochemical markers in breast cancer: which ones are clinically useful?. Clin Biochem 34 (5): 347–52. doi:10.1016/s0009-9120(00)00201-0. PMIDxa011522269. ↑ Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, et al. (2007). Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.. Cancer 110 (8): 1687–96. doi:10.1002/cncr.22981. PMIDxa017722109. ↑ Mohammadzadeh F, Mosayebi G, Montazeri V, Darabi M, Fayezi S, Shaaker M, et al. (2014). Fatty Acid Composition of Tissue Cultured Breast Carcinoma and the Effect of Stearoyl-CoA Desaturase 1 Inhibition.. J Breast Cancer 17 (2): 136–42. doi:10.4048/jbc.2014.17.2.136. PMCxa04090315. PMIDxa025013434. ↑ Ranson M, Andronicos NM (2003). Plasminogen binding and cancer: promises and pitfalls.. Front Biosci 8: s294–304. doi:10.2741/1044. PMIDxa012700073. ↑ Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, et al. (2013). High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients.. Breast Cancer Res Treat 137 (1): 319–27. doi:10.1007/s10549-012-2354-4. PMCxa03556743. PMIDxa023208590. 